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The Indian blood group system (ISBT 023) comprises one low-
prevalence antigen, Ina (IN:1), and five high-prevalence antigens: 
Inb (IN:2), INFI (IN:3), INJA (IN:4), INRA (IN:5), and INSL (IN:6). 
The antigens are located on the single-pass trans-membrane 
glycoprotein encoded by the CD44 gene. The present study 
was designed to identify the prevalence of the INRA– (IN:−5) 
phenotype and the frequency of its associated allele (IN*02.–
05) to inform us of the probability of finding antigen-negative 
donors and to assess the risk of antibody formation in transfusion 
recipients. Buffy coats were extracted from EDTA-anticoagulated 
whole blood samples, collected with consent from 5261 random 
blood donors in Surat, Gujarat, India. Standard serologic methods 
were performed with a modification allowing the use of antiserum 
generated by recycling the antibody augmented from the test 
already performed. A real-time polymerase chain reaction–
based assay was devised to genotype c.449G>A (p.Arg150His) 
single nucleotide variation in exon 5 of the CD44 gene. None 
of the 411 donors tested by serology or the 5261 donors tested 
molecularly were positive for the IN:−5 phenotype or the allele 
(IN*02.–05), respectively. The allele frequency estimate ranged 
from less than 1 in 10,522 (0.01%) to 1 in 3203 alleles (0.03%) in 
the study cohort (95% confidence interval, Poisson distribution). 
The absence of this rare allele in the present survey could be due 
to an ethnic difference, since the donors mostly came from the 
Hindu community, and the only case of the IN:−5 phenotype 
was found in the Muslim community. The p.150His variant may 
be either restricted to the index case family or only found in the 
Muslim community. Further studies in local subpopulations may 
provide more information on the frequency of p.150His and its 
immunogenicity in transfusion recipients if occurring among 
blood donors. Immunohematology 2020;36:129–132.
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The Indian blood group antigen Ina was recognized in the 
early 1970s when an antibody to a low-prevalence antigen was 
assigned the symbol after the name of the country where it 
was first found.1 It received blood group system status after 
its antithetical antibody, called Salis, directed to a high-
prevalence antigen (HPA) was reviewed and renamed as Inb.2 
The system was further expanded when four more HPAs, 
namely, INFI, INJA, INRA, and INSL, were found befitting 
to the system.3–5 Although Ina occurs in a low prevalence of 
2.3–4.5 percent in Indians and 11–12 percent in individuals 
from the Middle East,6,7 the other five antigens have their 
high prevalence among the population tested. The most cases 
with antibodies against these antigens had their origin in the 
Indian subcontinent—except INFI, which was found among 
Moroccan individuals.3
A transfusion recipient with an alloantibody to an 
HPA may have problems in finding compatible blood for 
transfusion.4,8 Keeping this in mind, we attempted a screening 
program on our blood donors for INRA (IN:5) to find units of 




Blood samples from 5261 healthy volunteers, aged 18 
years and older, were collected with informed consent at the 
Lok Samarpan Raktadan Kendra Blood Bank in Surat, Gujarat, 
India. Buffy coats were extracted from EDTA-anticoagulated 
whole blood samples. The buffy coats were pooled in batches 
of 20 and shipped to the Department of Transfusion Medicine 
at the U.S. National Institutes of Health (NIH) Clinical Center 
for DNA extraction (EZ1 DNA blood kit on a BioRobot EZ1 
Workstation; Qiagen, Valencia, CA) and molecular analysis.
Serologic Testing
Red blood cells (RBCs) from the healthy volunteers 
were tested with the serum from an original patient having 
an antibody to IN:5. Because the antibody agglutinated 
RBCs in low-ionic-strength saline (LISS) medium, serologic 
testing was performed by the LISS tube method. However, 
for any donor RBCs showing weak reactivity, particularly 
in the test supernatant (TS), the test was repeated by the 
indirect antiglobulin test (IAT) using original serum. No 
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dosage effect was observed, since the RBCs from the children 
of the proband (i.e., heterozygous for IN:5) reacted with the 
same agglutination strength as that of their father or other 
individuals outside the family (i.e., homozygous for IN:5). 
Because the antibody was in extremely short supply, we used 
the resource-conserving Nirantara approach, as reported 
earlier, by recycling the antibody.9 In brief, the test was initially 
performed as usual by mixing equal volumes of antiserum, 
LISS, and the donor’s RBC suspension and incubating for 15 
minutes at 37°C; the results were read after centrifugation. 
The test was centrifuged, and the TS was saved. In a separate 
procedure, the sensitized RBCs from the test were pooled, and 
an eluate was prepared by the ether elution method. The eluate 
antibody was mixed with the saved TS and used in screening 
further donors. While using TS in screening, no LISS was 
added, since it was already present from previous testing. If a 
donor’s RBCs showed weak agglutination in the test with TS, 
then the test was repeated using original antiserum and by the 
IAT. The test was validated for serologic activity and specificity 
by running the appropriate control in parallel with every batch 
of testing.
Molecular Screening
A real-time polymerase chain reaction (PCR)-based assay 
was devised to identify the frequency of the allele (IN*02.–05; 
p.150His) encoding the INRA– phenotype (IN:−5).10 Primers 
5 -́GCGGGCCTCTCTCCCAGCTATTGTTAACCA-3´ and 
5 -́ATTCTCCTTTCTGGACATAGCGGG-3´ were designed 
to genotype c.449G>A (p.Arg150His; rs771323886) single 
nucleotide variation (SNV) in exon 5 of the CD44 gene and 
applied to genomic DNA (gDNA). Controls included in each 
plate were heterozygous for c.449G>A from the children of 
the proband (INRA, IN:−5), homozygous for c.449G from a 
random specimen from an individual outside the family of 
the proband, and homozygous for c.449A from the proband 
herself.
An equal aliquot of buffy coat from 20 individuals was 
pooled after collection. gDNA was extracted and quantified 
for each pool. Analytical sensitivity was evaluated by spiking 
c.449A gDNA in pooled gDNA samples (heterozygous 
c.449G>A sample: homozygous c.449G sample; 1:0, 1:1, 
1:5, 1:10, 1:20, 1:30, and 0:1). Sensitivity of 100 percent was 
achieved in pools of size 20. Briefly, 20 ng of pooled gDNA was 
added to the real-time PCR assay. The pools were tested twice 
to confirm sensitivity and to ensure that individuals harboring 
c.449A variant are not missed.
Statistical Analysis
Ninety-five percent confidence intervals (CIs) for allele 
frequencies were calculated using the Poisson distribution.11
Results
The blood donor profile at the blood center where 
this study was carried out consisted mainly of the Hindu 
community; only a few sporadic donors came from the 
proband’s Muslim community.
Serologic Screen
Blood donor units were chosen to screen for the IN:−5 
phenotype, since there was a clear need to meet the possible 
requirement for transfusion. We had tested 411 donors by 
serology using the available antiserum obtained from the 
proband. None of these donors typed as IN:−5 by serologic 
testing. Because antiserum was not available to test more 
donors, further testing was carried out to directly screen for 
the variant allele coding the p.150His (IN*02.–05) allele using 
the molecular method.
Molecular Screen
We did not find a signal for the SNV indicative of the 
p.150His (IN*02.–05) among 5261 random blood donors 
in 264 pools. The c.449G allele frequency was 100 percent 
in this set of donors. We show an example of a positive real-
time genotyping result with a sample homozygous for c.449A 
in Figure 1. The data revealed that there was no discrepancy 
observed in the testing based on serology and by DNA-based 
molecular method among the samples tested.
Population Frequency
The allele frequency estimate, based on the data derived 
by the molecular screen, ranged from less than 1 in 10,522 
(0.01%) to 1 in 3203 alleles (0.03%) in the population (95% CI, 
Poisson distribution).
Discussion
The Indian blood group system comprises six antigens 
thus far, of which Ina is a low-prevalence antigen and Inb is an 
HPA, which together are an antithetical pair. Additionally, four 
other HPAs have been recognized, some of which were found 
to be clinically significant as to illicit immune response and to 
cause hemolytic transfusion reaction.8,12 Although an antibody 
to a low-prevalence antigen in a transfusion recipient may not 
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pose a problem in finding units of antigen-negative blood 
for transfusion, an antibody to an HPA typically presents an 
enormous challenge to provide units of blood for transfusion.4,8 
The aim of the present study was to screen for blood donors 
should a patient (the proband) require appropriate compatible 
units of blood for transfusion. The study also aimed to find 
the prevalence of the variant allele (IN*02.–05; p.150His) 
encoding the IN:−5 phenotype and to assess the risk of 
antibody formation in transfusion recipients.
None of the donors screened in the present study by sero-
logic and molecular methods showed the IN:−5 phenotype. 
The Genome Aggregation Database (gnomAD) lists c.449A 
allele frequency as less than 0.01 percent among 122,365 
individuals, with c.449A (p.150His)-positive individuals found 
in East Asian, South Asian, and Finnish populations.13
A limitation of our study is that the vast majority of 
the tested donors (99.9%) came from the Hindu Gujarati 
community. The IN:−5 proband has been identified in the 
Rayeen community, an endogamous caste group of the Sunni 
Muslim sect. The parents of the proband denied consanguinity 
in their marriage. Although the Rayeen community is mostly 
settled in Uttar Pradesh, a northern state of India, some of the 
families have migrated to Gujarat state to earn their livelihood 
through their ancestral business as greengrocers. If efforts 
were made to screen the members of the proband’s Rayeen 
community, the chance of finding this rare phenotype or allele 
of interest would have been greater.
A large-scale screening program requires material 
resources including antiserum and other reagents, and this 
need made it difficult for us to meet some of the requirements. 
The use of a resource-conservative strategy in serologic testing 
by the Nirantara method and the use of pooled buffy coats 
for DNA study (as was earlier used on blood specimens) may 
prove not only economical but also feasible to accomplish such 
a screening program in resource-scarce areas.9,14
Conclusions
We did not detect this SNV among 5261 random blood 
donors in the state of Gujarat in western India. Because we 
originally observed the INRA– phenotype with the p.150His 
variant allele in a Muslim patient, it is conceivable that the trait 
is either restricted to the index case family or only common 
in the Muslim community to which the patient belongs. 
Further studies in the local subpopulations may provide more 
information on the frequency of the IN*02.–05 allele and the 
immunogenicity of IN:5 in transfusion recipients, if occurring 
among blood donors.
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